XFRA CAPITAL ADJUSTMENT INFORMATION

Realtime	Geld	Brief	Zeit
	0,319	0,342	10:17

Realtime

Geld

Brief

Zeit

0,319

0,342

10:17

XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026

Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026
The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026

Das Instrument 5JD0 SE0023261292 EXPRES2ION BIOTECH HLDG EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026
The instrument 5JD0 SE0023261292 EXPRES2ION BIOTECH HLDG EQUITY is traded ex capital adjustment on 13.04.2026

Das Instrument 52X SE0014401014 MAGLE CHEMOSWED HOLDING EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026
The instrument 52X SE0014401014 MAGLE CHEMOSWED HOLDING EQUITY is traded ex capital adjustment on 13.04.2026

Das Instrument YAJ0 AU0000458226 KAIROS MINERALS DEF. EQUITY wird cum Kapitalmassnahme gehandelt am 13.04.2026 und ex Kapitalmassnahme am 14.04.2026
The instrument YAJ0 AU0000458226 KAIROS MINERALS DEF. EQUITY is traded cum capital adjustment on 13.04.2026 and ex capital adjustment on 14.04.2026

Energiepreisschock - Diese 3 Werte könnten langfristig abräumen!

Die Eskalation im Iran-Konflikt hat die Energiepreise mit voller Wucht nach oben getrieben. Was zunächst nach einer kurzfristigen Reaktion aussah, entwickelt sich zunehmend zu einem strukturellen Problem: Die Straße von Hormus ist blockiert, wichtige LNG- und Ölanlagen stehen still oder werden gezielt angegriffen. Eine schnelle Entspannung ist nicht in Sicht – im Gegenteil, die Lage spitzt sich weiter zu.

Für die Weltwirtschaft bedeutet dies wachsende Risiken. Steigende Energiepreise erhöhen den Inflationsdruck, gefährden Zinssenkungen und bringen die ohnehin hoch bewerteten Aktienmärkte ins Wanken. Doch wo Risiken entstehen, ergeben sich auch Chancen.

Denn von einem dauerhaft höheren Energiepreisniveau profitieren nicht nur Öl- und Gasunternehmen. Auch Versorger, erneuerbare Energien sowie ausgewählte Rohstoff- und Agrarwerte rücken in den Fokus. In diesem Umfeld könnten gezielt ausgewählte Unternehmen überdurchschnittlich profitieren – unabhängig davon, ob die Krise anhält oder nicht.

In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die genau dieses Profil erfüllen: Krisenprofiteure mit solidem Geschäftsmodell, attraktiver Bewertung und langfristigem Potenzial.

Jetzt den kostenlosen Report sichern – und Ihr Depot auf den Energiepreisschock vorbereiten!

Hier klicken

Zeit	Aktuelle Nachrichten
06:00	XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026	Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026 The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026Das... ► Artikel lesen
Di	ExpreS2ion Biotech Holding AB: The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead cancer program, and publishes terms for the rights issue	Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by... ► Artikel lesen
01.04.	ExpreS2ion Biotech Holding AB: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 1 April 2026	Hørsholm, Denmark, 1 April 2026 - Today, on 1 April 2026, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting (the "EGM"). The notice to convene the... ► Artikel lesen
25.03.	ExpreS2ion Biotech Holding AB: ExpreS2ion reports consistent, durable anti-HER2 responses; advances ES2B-C001 Phase I after independent DSMB review	Hørsholm, Denmark, 25 March 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of active immunotherapy... ► Artikel lesen
27.02.	Expres2ion Biotech Holding AB: Expres2ion Announces The Board Of Directors' Intention To Resolve On A Rights Issue Of Units Of Approximately Sek 53 Million	THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen

Zeit

Aktuelle Nachrichten

06:00

XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026

ExpreS2ion Biotech Holding AB: The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead cancer program, and publishes terms for the rights issue

Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by...
► Artikel lesen

01.04.

ExpreS2ion Biotech Holding AB: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 1 April 2026

Hørsholm, Denmark, 1 April 2026 - Today, on 1 April 2026, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting (the "EGM"). The notice to convene the...
► Artikel lesen

25.03.

ExpreS2ion Biotech Holding AB: ExpreS2ion reports consistent, durable anti-HER2 responses; advances ES2B-C001 Phase I after independent DSMB review

Hørsholm, Denmark, 25 March 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of active immunotherapy...
► Artikel lesen

27.02.

Expres2ion Biotech Holding AB: Expres2ion Announces The Board Of Directors' Intention To Resolve On A Rights Issue Of Units Of Approximately Sek 53 Million

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,...
► Artikel lesen

Zeit	Aktuelle Nachrichten
06:00	XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026		Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026 The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026Das... ► Artikel lesen

Zeit

Aktuelle Nachrichten

06:00

XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026

Zeit	Aktuelle Nachrichten
06:00	XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026	Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026 The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026Das... ► Artikel lesen
Fr	Magle Chemoswed Holding AB: Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ)	Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 10 April 2026, held an Extraordinary General Meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in... ► Artikel lesen
27.03.	Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2025	Magle Group's Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment. Q4 2025 KEY INDICATORSNet Sales amounted... ► Artikel lesen
25.03.	Magle Chemoswed Holding AB: Magle Group's Board Of Directors Has Resolved On A Rights Issue Of Approx Sek 40 Million And Agreed A Revised Financing Package	THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen
18.02.	Magle Chemoswed Holding AB: Magle Group Issues Profit Warning Ahead of Q4 and Full-Year 2025 Results	Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026. This follows the Group's... ► Artikel lesen

Zeit

Aktuelle Nachrichten

06:00

XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026

Magle Chemoswed Holding AB: Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ)

Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 10 April 2026, held an Extraordinary General Meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in...
► Artikel lesen

27.03.

Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2025

Magle Group's Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment. Q4 2025 KEY INDICATORSNet Sales amounted...
► Artikel lesen

25.03.

Magle Chemoswed Holding AB: Magle Group's Board Of Directors Has Resolved On A Rights Issue Of Approx Sek 40 Million And Agreed A Revised Financing Package

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH...
► Artikel lesen

18.02.

Magle Chemoswed Holding AB: Magle Group Issues Profit Warning Ahead of Q4 and Full-Year 2025 Results

Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026. This follows the Group's...
► Artikel lesen

Unternehmen / Aktien	Kurs	%
EXPRES2ION BIOTECH HOLDING AB	0,489	-17,68 %
LUXBRIGHT AB	0,010	-18,64 %
MAGLE CHEMOSWED HOLDING AB	0,358	+0,56 %

Unternehmen / Aktien

Kurs

EXPRES2ION BIOTECH HOLDING AB

0,489

-17,68 %

LUXBRIGHT AB

0,010

-18,64 %

MAGLE CHEMOSWED HOLDING AB

0,358

+0,56 %

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche